X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, AbbVie will explore Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapies in solid tumor indications and autoimmune diseases.
Lead Product(s): CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 06, 2024
Details:
Under the agreement, Calibr is granting Gates MRI an exclusive license to continue the development of the investigational compound CLB073 for tuberculosis treatment.
Lead Product(s): CLB073
Therapeutic Area: Infections and Infectious Diseases Product Name: CLB073
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gates MRI
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 15, 2023
Details:
Mitopure® is a highly pure form of Urolithin A; a bioactive dietary metabolite that is produced by gut bacteria after eating certain foods, such as the pomegranate, though it is difficult for most people to get enough of this specialized nutrient from food alone.
Lead Product(s): Urolithin A
Therapeutic Area: Musculoskeletal Product Name: Mitopure
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Amazentis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
The initial SARS-CoV-2 research program at Calibr, the drug discovery and development division of Scripps Research, was supported by funding from the Bill & Melinda Gates Foundation to deliver next generation oral antiviral treatments.
Lead Product(s): Antiviral Therapeutic
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2022
Details:
Under the terms of the multi-year collaboration agreement, Scripps will conduct research and development activities, and Bridge Biotherapeutics will retain an exclusive option to acquire worldwide license and patent rights from the research program.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Recipient: Bridge Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 08, 2022
Details:
EOD-GT8 60mer showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
Lead Product(s): eOD-GT8 60mer,AS01B
Therapeutic Area: Infections and Infectious Diseases Product Name: eOD-GT8 60mer
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: IAVI
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2021
Details:
Scientists from Scripps Research have created drug-like compounds that, in human cell studies, bind and destroy the coronavirus’ clutch-like device which helps in viral replication, thus ceasing its spread.
Lead Product(s): C5-RIBOTAC
Therapeutic Area: Infections and Infectious Diseases Product Name: C5-RIBOTAC
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Details:
The study, published in Science, is the first to map a human antibody’s interaction with the new coronavirus at near-atomic-scale resolution.
Lead Product(s): SARS-CoV-2 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
